44.48
price down icon1.61%   -0.73
after-market アフターアワーズ: 44.48
loading
前日終値:
$45.21
開ける:
$44.57
24時間の取引高:
596.85K
Relative Volume:
0.71
時価総額:
$3.16B
収益:
$58.89M
当期純損益:
$-240.88M
株価収益率:
-14.35
EPS:
-3.1
ネットキャッシュフロー:
$-239.96M
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
-8.08%
6か月 パフォーマンス:
+16.53%
1年 パフォーマンス:
+14.05%
1日の値動き範囲:
Value
$43.87
$45.15
1週間の範囲:
Value
$42.87
$46.34
52週間の値動き範囲:
Value
$19.45
$53.27

Kymera Therapeutics Inc Stock (KYMR) Company Profile

Name
名前
Kymera Therapeutics Inc
Name
セクター
Healthcare (1164)
Name
電話
857-285-5314
Name
住所
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Name
職員
208
Name
Twitter
Name
次回の収益日
2025-02-21
Name
最新のSEC提出書
Name
KYMR's Discussions on Twitter

KYMR を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KYMR
Kymera Therapeutics Inc
44.48 3.16B 58.89M -240.88M -239.96M -3.10
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.85 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
567.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
314.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.24 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
250.30 28.51B 3.81B -644.79M -669.77M -6.24

Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-06-03 アップグレード B. Riley Securities Neutral → Buy
2025-06-03 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-06-02 アップグレード BofA Securities Neutral → Buy
2025-05-20 再開されました Stifel Buy
2025-03-13 開始されました Citigroup Buy
2024-12-10 開始されました BTIG Research Buy
2024-12-06 開始されました BMO Capital Markets Market Perform
2024-12-02 アップグレード Wells Fargo Equal Weight → Overweight
2024-11-18 開始されました Stephens Overweight
2024-09-09 再開されました Leerink Partners Outperform
2024-08-26 アップグレード Wolfe Research Peer Perform → Outperform
2024-04-22 開始されました Oppenheimer Outperform
2024-02-15 開始されました Wolfe Research Peer Perform
2024-01-04 アップグレード JP Morgan Neutral → Overweight
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-12-19 ダウングレード Wells Fargo Overweight → Equal Weight
2023-06-30 開始されました Truist Buy
2023-05-05 アップグレード Raymond James Mkt Perform → Outperform
2022-12-06 ダウングレード Credit Suisse Outperform → Neutral
2022-11-08 開始されました Raymond James Mkt Perform
2022-08-15 開始されました Jefferies Buy
2022-08-03 開始されました Goldman Buy
2022-07-20 開始されました SVB Leerink Mkt Perform
2022-04-28 開始されました Credit Suisse Outperform
2022-03-10 開始されました JP Morgan Neutral
2022-02-10 開始されました Wells Fargo Overweight
2021-09-30 開始されました B. Riley Securities Neutral
2021-09-30 開始されました Stifel Buy
2021-09-10 ダウングレード BofA Securities Buy → Neutral
2021-05-21 開始されました UBS Buy
2021-04-14 開始されました Berenberg Buy
2020-12-04 開始されました H.C. Wainwright Buy
2020-09-15 開始されました BofA Securities Neutral
2020-09-15 開始されました Cowen Outperform
2020-09-15 開始されました Guggenheim Buy
2020-09-15 開始されました Morgan Stanley Equal-Weight
すべてを表示

Kymera Therapeutics Inc (KYMR) 最新ニュース

pulisher
Jun 15, 2025

When (KYMR) Moves Investors should Listen - news.stocktradersdaily.com

Jun 15, 2025
pulisher
Jun 14, 2025

Kymera draws upgrades after early-stage data for anti-inflammatory agent - MSN

Jun 14, 2025
pulisher
Jun 13, 2025

Kymera Therapeutics soars 35% on positive phase 1 results for oral STAT6 degrader KT-621 - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Analysts Can't Get Enough of These Little-Known Biopharma Stocks - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Analysts Can't Get Enough of These Little-Known Biopharma Stocks - MarketBeat

Jun 12, 2025
pulisher
Jun 11, 2025

Morgan Stanley Maintains Hold Rating on Kymera Therapeutics (KYMR), Keeps PT - MSN

Jun 11, 2025
pulisher
Jun 10, 2025

Kymera jumps 16% as it prepares to release phase 1 data on inflammatory diseases asset - MSN

Jun 10, 2025
pulisher
Jun 08, 2025

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? - Benzinga

Jun 08, 2025
pulisher
Jun 07, 2025

B. Riley Research Analysts Lower Earnings Estimates for KYMR - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Top 10 NASDAQ Stocks with Strong Growth Potential by Kalkine - Kalkine Media

Jun 06, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Takes Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Q2 EPS Forecast for Kymera Therapeutics Boosted by Analyst - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Wall Street Shows Love for Kymera Stock After Biotech’s Promising Drug Trial - Barron's

Jun 05, 2025
pulisher
Jun 05, 2025

Citi Raises Kymera (KYMR) Price Target After Positive Drug Data, Keeps Buy Rating - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

BofA Upgrades Kymera Therapeutics (KYMR) to Buy, Lifts PT to $51 - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Clinical Trial of KT-621 - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics, Inc.’s (KYMR) Upgraded to Buy Following Positive Phase 1 Results for Oral STAT6 Degrader - MSN

Jun 04, 2025
pulisher
Jun 04, 2025

JPMorgan Chase & Co. Issues Positive Forecast for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Overweight” at Morgan Stanley - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), CSPC Pharmaceutical Group (CHJTF) - The Globe and Mail

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded by B. Riley to “Buy” Rating - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

B. Riley Securities Upgrades Kymera Therapeutics (KYMR) - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics Executives and Directors Sell Shares - TradingView

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race - insights.citeline.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera stock draws upgrades after trial data (KYMR:NASDAQ) - Seeking Alpha

Jun 03, 2025
pulisher
Jun 03, 2025

Morgan Stanley upgrades Kymera stock rating, raises price target By Investing.com - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - TradingView

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera STAT6 Degrader Phase 1 Data a 'Key De-Risking Event,' Morgan Stanley Says - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Ta - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Receives Analyst Upgrade and Price Target Boost | KYMR Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (NASDAQ:KYMR) Upgraded to “Buy” at Bank of America - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

What 6 Analyst Ratings Have To Say About Kymera Therapeutics - Nasdaq

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel Adjusts Price Target on Kymera Therapeutics to $68 From $55, Maintains Buy Rating - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Sees Price Target Raised by JP Morgan | KYMR Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Receives Upgraded Target Price and Po - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

JPMorgan Raises Kymera Therapeutics (KYMR) Target Price Amid Positive Phase 1 Data | KYMR Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Morgan Stanley Upgrades Kymera Therapeutics to Overweight From Equalweight, Raises Price Target to $79 From $49 - MarketScreener

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics (KYMR) Shares Boosted by Positive KT-621 Dat - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Wells Fargo reiterates overweight rating on Kymera Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

Where are the Opportunities in (KYMR) - news.stocktradersdaily.com

Jun 03, 2025
pulisher
Jun 03, 2025

Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera reports promising Phase 1 results for KT-621 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Kymera Therapeutics, Inc. (KYMR) to Announce KT-621 Phase 1 Results on June 2, 2025 - MSN

Jun 03, 2025
pulisher
Jun 02, 2025

These 10 Stocks Blew Past Expectations - Insider Monkey

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera’s STAT6 Degrader for Inflammatory Disease Shows Early Success in Phase I - Genetic Engineering and Biotechnology News

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgra - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera Therapeutics (KYMR) Gains Favor with Morgan Stanley Upgrade | KYMR Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Kymera, with new data, takes early step toward a Dupixent-like pill - BioPharma Dive

Jun 02, 2025
pulisher
Jun 02, 2025

TRUIST SECURITIES MAINTAINS BUY RATING ON KYMERA STOCK AFTER POSITIVE STUDY RESULTS - Investing.com UK

Jun 02, 2025

Kymera Therapeutics Inc (KYMR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Kymera Therapeutics Inc (KYMR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
BAKER BROS. ADVISORS LP
Director
Jun 30 '25
Buy
44.00
655,500
28,842,000
6,117,295
Ridloff Elena
Director
Jun 11 '25
Option Exercise
20.29
4,500
91,305
4,500
Ridloff Elena
Director
Jun 11 '25
Sale
50.00
4,500
225,000
0
$21.40
price down icon 2.10%
$35.84
price down icon 0.78%
$25.00
price down icon 3.40%
$98.18
price up icon 1.57%
$112.89
price down icon 0.90%
biotechnology ONC
$250.30
price down icon 1.22%
大文字化:     |  ボリューム (24 時間):